Autres langues Asarina Pharma AB

Actions

ASAP

SE0011641794

Temps Différé Nasdaq Stockholm Autres places de cotation 16:29:36 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,892 ^SEK	-6,11 %		-1,11 %	+1,36 %

27/02	Asarina Pharma AB (publ) publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Asarina Pharma AB (publ) publie ses résultats pour le semestre clos le 30 juin 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	27/02
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	30/11
Asarina Pharma updates on partnering and financials	16/11
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	23/08/23
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23
ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	24/05/23
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	22/05/23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	08/05/23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	05/05/23
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	05/05/23
Asarina Pharma AB (publ) releases Annual Report 2022	01/05/23
Asarina Pharma AB (publ) releases Annual Report 2022	28/04/23
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	18/04/23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	03/04/23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	01/04/23
Asarina Pharma AB (publ) releases Year-End Report 2022	27/02/23
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23
Last Patient Last Visit for landmark Tourette Syndrome study	02/02/23
Asarina Pharma - Patient recruitment completed in landmark Tourette syndrome study	17/10/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Asarina Pharma AB

Actions

ASAP

SE0011641794

Autres langues

Filtres